Skip to main content
BC Innovations
Feature Story

The flipside of CD47

OSE Immunotherapeutics blocks SIRPA to feed and rewire myeloid cells in cancer

While a growing tally of companies seeks to promote tumor phagocytosis by blocking the "don't eat me" signal CD47 on cancer cells, OSE Immunotherapeutics S.A. (Euronext:OSE) is flipping that approach on its head by targeting signal regulatory protein alpha (SIRPA), a CD47 receptor on phagocytic myeloid cells. The company thinks its anti-SIRPA mAb, dubbed Effi-DEM, goes beyond the CD47 approach because it not only helps phagocytes eat tumor cells, but also turns up their immune reactivity.

"It shares one part of its mechanism of action with anti-CD47 antibodies, because it enhances phagocytosis by macrophages," said Bernard Vanhove, OSE's COO. "But importantly and surprisingly, it acts to convert anti-inflammatory cells into non-suppressive cells which have an inflammatory profile."

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Deals

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Sales & Marketing

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Other News

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.